Recommendations
1	Primary care clinicians should pro-actively identify suspected severe asthma patients for optimization (including appropriate referral)
2	Pharmacy (either community- or hospital-based) should be utilized to help identify potential severe asthma patients
3	Asthma patients that have a history of overuse of SABA and/or repeat OCS therapies should be assessed for severe asthma
4	Access to diagnostic tools (including spirometry, lung function test etc.) within 4 weeks of request should be an expected standard within Canada
5	A consistent pathway for referral of suspected severe asthma patients should be in place across Canada with clearly defined criteria and acceptable waiting time
6	All patients should receive education about their asthma from an asthma educator
7	The choice of biologic therapy should be driven by disease phenotype, which is determined by clinical history, comorbidities, biomarkers and spirometry
8	Initiation of a biologic therapy should be within 2–4 weeks of approval
9	National Pan-Canadian data collection about severe asthma should be established
10	Patients should be empowered to work together with their HCPs, through shared decision-making tools, to manage their symptoms and control their asthma